How do gene expression profiling results influence your recommendations for surveillance intensity in patients with early-stage melanoma?

Currently, next-generation sequencing (NGS) is not used to determine surveillance intensity. The only molecular test that may have some impact on surveillance intensity is circulating tumor DNA (ctDNA), such as Signatera from Natera. Signatera is more established in solid tumor types that are known ...

From my standpoint, it’s the main use. Sentinel nodes do not govern how long you’re going to live. They’re a predictor of things, but they are not a governor of that. So the risk of recurrence is highly important, and we get an individualized number for that in stage I and stage II.

A very low-risk p...

Gene expression profiling (GEP) defines surveillance intensity for early-stage melanoma. Early-stage melanoma (i.e., stage I) would not typically be expected to metastasize or recur. Patients at high genomic risk of recurrence should be surveilled more closely, including self-skin exams in between r...